BPC-157 vs TB-500: Differences in Evidence, Status and Regulation
BPC-157 and TB-500 are compared below on structure, research stage, registered clinical studies, and regulatory status, using the same sourced data shown on each entry page. This comparison is descriptive and does not rank either peptide.
Comparison table
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Category | Tissue repair (research) | Tissue repair (research) |
| Research status | Research only | Research only |
| Origin | No data | No data |
| Amino acids | 15 | No data |
| Molecular weight | No data | No data |
| Overall evidence level | No data | No data |
| Human evidence rows in our table | No data | No data |
| Registered studies (ClinicalTrials.gov) | 3 | 18 |
| Most advanced registered phase | Phase 2 | Phase 3 |
| Half-life (sourced) | No data | No data |
| Status: United States | No data | No data |
| Status: European Union | No data | No data |
| Status: United Kingdom | No data | No data |
| Status: WADA (sport) | No data | No data |
Key differences
- ClinicalTrials.gov lists 3 registered studies matching BPC-157 and 18 matching TB-500.
- The most advanced registered phase is Phase 2 for BPC-157 and Phase 3 for TB-500.
Entry pages
Full sources, evidence tables, and regulatory details are on each entry page: BPC-157 and TB-500.
This comparison does not rank the two peptides and does not suggest that either one is appropriate for any use.